Norgine Ventures Investment Team

ava_04

Peter Stein is the Chairman and Chief Executive and principal shareholder of Norgine, an independent, specialty pharmaceutical company with operations throughout Europe. In 2012 Peter founded Norgine Ventures. Prior to joining Norgine in 1987, Peter was a co-founder and Vice President of Invitron Corporation, a contract biomanufacturer formed as a spin-off from the Monsanto Company. He started his pharmaceutical career with Centocor.

Peter holds BA and MA degrees in Chemistry from Harvard University and an MBA from Stanford University.

ava_04

Peter Martin joined Norgine in 2004. Peter has worked in a variety of sales, marketing, research and development and general management roles in the pharmaceutical industry in Europe and the US for the past thirty-six years. He has always been keenly interested in the interface between the healthcare industry and the individual patient.

Peter has an MA in Chemistry from Oxford University and an MBA from the Open University.

ava_04

Julien Michaux joined Norgine Ventures from Lazard where as a member of the Healthcare M&A team he advised many European and US clients on merger and acquisition transactions. Julien joined Lazard in 2005 from J&J Pharmaceuticals where he worked as part of the M&A team. Julien has 11 years of experience in the Healthcare industry. He started his career with Procter & Gamble.

Julien holds an MS in Engineering from ICAM in France and an MBA from the Anderson School at UCLA.

ava_04

Jackie joined Norgine Ventures in 2019 from Norgine Pharma, where she worked for ten years. Her last role was Head of Corporate Finance, responsible for group treasury, strategic planning and finance lead on in/out licensing products and company acquisitions. Previously, ten years at GlaxoSmithKline plc in various finance roles in the UK and US.

Jackie holds a B.Sc. in Engineering from Cornell University and holds professional qualifications in accountancy, ACMA and treasury, ACT.

ava_04

Grethe joined Norgine Ventures in 2019 from Norgine Pharma, where she was Programme Manager in Clinical Development for two years and continues to lend her expertise for special projects. Previously, she worked 12 years in R&D at GE Healthcare, the last seven years hereof as a Project Leader with accountability for driving projects from discovery through Phase 2a.

Grethe started her career in academic research and is a Pharmacist from the Royal Danish School of Pharmacy.

ava_04

Iakhia joined Norgine Ventures in 2020. Prior to Norgine Ventures, Iakhia spent eight years at Goldman Sachs in the investment banking division in London as part of the Global Healthcare Group. He started his career at Institut Francais Du Petrole in France as a researcher, followed by KPMG.

Iakhia holds a MSc in Engineering from State University of Oil and Gas in Russia (with distinction) and a BSs from Higher School of Economics in Russia.

ava_04

Moritz joined Norgine Ventures in 2016. He started his finance career as an analyst on the structured products team at Schroders Private Bank in London, before joining the investment team of a family office in New York.

Moritz holds a PhD and MSc degree in Physics from Imperial College London and a BSc from The University of Edinburgh.

ava_04

Kristine joined Norgine Ventures in 2016 from the Lazard Healthcare M&A team. Prior to Norgine Ventures, worked at Royalty Pharma and DRI Capital and gained experience in pharmaceutical royalty monetisation.

Kristine holds a BSc Hons in Cell Biology from the University of St. Andrews.